.RESEARCH HIGHLIGHT.06 August 2024.
A big randomized regulated trial along with cisgender women highlights the obstacles of obedience to a day-to-day oral preexposure prevention program and shows that twice-yearly injection of lenacapavir may preserve reliable HIV prevention levels over 6 months.